image description

Tag: Aurinia

Data Shows Voclosporin Preserves Kidney Function for Three Years

July 19,2023 The LRA is pleased to share news announced by Aurinia Pharmaceuticals of published results showing that the lupus treatment, voclosporin (Lupkynis) preserved kidney function up to three years among lupus nephritis.  These results of the Phase 3, double-blind, placebo-controlled AURORA 2 extension study were published in the official peer-reviewed professional journal of the […] Read More

LRA Congratulates Aurinia on Published Results with FDA-Approved Lupkynis™

May 10, 2021 The highly prestigious medical journal The Lancet published the results of Aurinia’s Phase 3 AURORA 1 study testing Lupkynis™ (voclosporin) in adults with lupus nephritis. Lupkynis was approved by the U.S. Food and Drug Administration based on these data. The AURORA 1 study results showed that Lupkynis in combination with the commonly used […] Read More

Promising News from Major Medical Meeting, EULAR

Updated June 5, 2020 One of the largest meetings for rheumatologists went virtual this year to enable scientists from around the world to share their latest findings amid the COVID-19 pandemic. EULAR, the e-Congress of the European League Against Rheumatism, runs June 3 -6, and LRA is pleased to share promising results from clinical trials […] Read More

LRA Shares Excitement For What’s Ahead in Lupus Nephritis

January 16, 2020 Up to half of people with lupus will have lupus nephritis – damage to the kidneys that affects the ability to clear the body of wastes and toxins. In 2020, we expect to see significant progress in new drug development for lupus and lupus nephritis in particular with submissions for FDA approval in […] Read More

LRA Celebrates Major Research Breakthroughs in 2019

January 7, 2020 2019 was a phenomenal, breakthrough year for lupus research on both the clinical development and basic science fronts. The Lupus Research Alliance (LRA) is incredibly proud that every new discovery leading to a brand new medicine for lupus had its origin in work funded by LRA years ago. The past 12 months delivered many […] Read More

Potential Lupus Nephritis Treatment Works Well with Mycophenolate Acid

November 8, 2019 Aurinia Pharmaceuticals announced results from a study showing that their investigational drug voclosporin did not significantly impact the levels of mychophenolate acid (MPA), the main ingredient  in the common standard treatment mycophenolate mofetil (CellCept®) for lupus nephritis. The drug-drug interaction (DDI) study was requested by the Food and Drug Administration to measure […] Read More

Good News from Aurinia Pharmaceuticals for Lupus Nephritis

September 25, 2018 Congratulations to Aurinia Pharmaceuticals for completing patient enrollment in the AURORA Phase 3 clinical trial ahead of schedule.  The company reported in a press release issued today that due to high patient demand, the target number of patients was surpassed with 358 lupus nephritis (LN) patients enrolled in sites across 27 countries. […] Read More

Aurinia Announces Voclosporin Meets 48-Week Remission Endpoints

Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH / TSX:AUP) (“Aurinia” or the “Company”), a clinical stage biopharmaceutical company focused on the global immunology market, today announced top-line results from its Phase IIb AURA-LV (AURA) study in lupus nephritis (LN). At 48 weeks, the trial met the complete and partial remission (“CR”/ “PR”) endpoints, demonstrating statistically significantly greater CR […] Read More